Clinical trial
Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Maintenance of Remission in Patients With Ulcerative Colitis
NCT00746447 is registered in ClinicalTrials.gov with Dr. Falk Pharma GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Maintenance of Remission in Patients With Ulcerative Colitis
- Lead sponsor
- Dr. Falk Pharma GmbH
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2005
- Completion date
- March 31, 2008
- Enrollment
- 648 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.